WebObjective: In the Phase III PAOLA study (clinicaltrials.gov: NCT01137682), enrolled patients had uncontrolled acromegaly despite ≥6 months of octreotide/lanreotide treatment before … WebPAOLA-1 met its primary endpoint in the IT T population demonstrating a statistically significant improvement in investigator assessed PFS for Lynparza (olaparib) + bevacizumab compared to placebo + bevacizumab (HR 0.59, 95% CI 0.49–0.72, P <0.0001 with a median of 22.1 months vs. 16.6 months respectively) 1 Adverse events remain …
Association of location of BRCA1 and BRCA2 mutations with …
WebNov 9, 2024 · This is a Phase III randomised, double-blind, multi-centre study to evaluate the efficacy and safety of durvalumab in combination with standard of care platinum based chemotherapy and bevacizumab followed by maintenance durvalumab and bevacizumab or durvalumab, bevacizumab and olaparib in patients with newly diagnosed advanced … WebIn contrast, the subgroup analyses of the PAOLA-1 study showed that maintenance therapy with bevacizumab and olaparib resulted in a median improvement in the PFS of 19.5 months in the patients with HRD-positive tumors (including somatic BRCA1/2 mutations) compared with the placebo-controlled group. dimmitt chevrolet used trucks
Olaparib plus Bevacizumab as First-Line …
WebSep 30, 2024 · In the subgroup of patients with HRD-positive tumours, median PFS in PAOLA-1 was 37.2 months for olaparib plus bevacizumab versus 17.7 months for bevacizumab (HR 0.33; 95% CI: 0.25–0.45), 11 and in PRIMA was 21.9 months for maintenance niraparib versus 10.4 months for placebo (HR 0.43; 95% CI: 0.31–0.59; p < … WebJun 19, 2024 · For example, the ongoing phase III PAOLA-1 study, is testing the combination of olaparib and bevacizumab (Avastin) as a first-line maintenance treatment for patients with advanced, stage... WebSep 21, 2024 · The recommendation for approval was based on data from a biomarker subgroup analysis of the phase 3 PAOLA-1 trial (NCT02477644), which had been … dimmitt children\u0027s healthy pantry